25 results
Keyword Mvasi Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Mvasi
bevacizumab, Carcinoma, Renal Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms
Date of authorisation: 15/01/2018,
, 
, Revision: 11, Authorised, Last updated: 06/09/2021
Mvasi Cancer Neoplasms Urogenital … Mvasi … Mvasi, INN-bevacizumab 9 November … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017
CHMP, Last updated: 10/11/2017Mvasi … -
List item
National expert: Stefania Catone, Italian Medicines Agency
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 22.78 KB | PDF
157-167. 8) "Pentavalent MVA-SIV vaccine in cynomolgus monkeys … -
List item
Withdrawn application: Kyomarc
bevacizumab, date of withdrawal: 17/10/2017, Initial authorisation, Last updated: 10/11/2017application for another medicine, Mvasi, which is also a biosimilar … -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 May 2022 (updated)
European Medicines Agency, Amsterdam, the Netherlands, from 16/05/2022 to 19/05/2022, Last updated: 16/05/2022 -
List item
List of medicines under additional monitoring (updated)
Last updated: 25/04/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 September-1 October 2020
Virtual meeting, from 28/09/2020 to 01/10/2020, Last updated: 29/09/2020 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 March 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/03/2021 to 25/03/2021, Last updated: 07/12/2021 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 02/05/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 September 2021
European Medicines Agency, Amsterdam, the Netherlands, from 27/09/2021 to 30/09/2021, Last updated: 27/02/2018 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 08/02/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 September 2018
European Medicines Agency, London, UK, from 03/09/2018 to 06/09/2018, Last updated: 13/03/2014 -
List item
European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) meeting with all eligible organisations
European Medicines Agency, London, UK, 22/11/2017, Last updated: 11/12/2017 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021
PRAC, Last updated: 01/10/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 25-29 January 2021
Virtual meeting, from 25/01/2021 to 29/01/2021, Last updated: 04/03/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 6-9 November 2017
European Medicines Agency, London, UK, from 06/11/2017 to 09/11/2017, Last updated: 06/01/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 July 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/07/2021 to 22/07/2021, Last updated: 07/10/2021 -
List item
Annual reports and work programmes
Last updated: 27/01/2022 -
List item
News: EMA 2017 annual report published
Last updated: 02/05/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 December 2017
European Medicines Agency, London, UK, from 11/12/2017 to 14/12/2017, Last updated: 06/01/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 December 2020
Virtual meeting, from 07/12/2020 to 10/12/2020, Last updated: 04/11/2019 -
List item
Public data from Article 57 database
Last updated: 02/06/2021 -
List item
CHMP: meeting archive 2016-2018
Last updated: 26/02/2020